Head-to-head evidence
HS-20094 vs VK2735
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
HS-20094
Developed by Hansoh Pharmaceutical Group
NCT06839664 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07431086 (registry estimate)
VK2735
Developed by Viking Therapeutics
NCT06828055 · Phase 2 · completed
This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2027 · NCT07104500 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20094's landscape · VK2735's landscape